https://www.clinicaltrialsarena.com/news/padcev-data-urothelial-cancer/
Padcev meets primary goal Seattle Genetics-Astellas' urothelial cancer trial
Sep 21, 2020 - Seattle Genetics and Astellas Pharma have reported that Padcev achieved its primary endpoint of overall survival in a Phase III trial in urothelial cancer.
seattle geneticsurothelial cancerpadcevmeetsprimary
https://www.schaeffersresearch.com/content/news/2016/12/27/buzz-stocks-tesla-motors-inc-endologix-inc-and-seattle-genetics-inc
Buzz Stocks: Tesla Motors Inc, Endologix, Inc., and Seattle Genetics, Inc.
Today's stocks to watch in the news include electric car maker Tesla Motors Inc (NASDAQ:TSLA), medical device stock Endologix, Inc. (NASDAQ:ELGX), and biotech...
tesla motorsseattle geneticsbuzzstocksinc
https://www.fiercebiotech.com/biotech/seattle-genetics-pens-2b-pact-to-bag-immunomedics-drug
Seattle Genetics pens $2B pact to bag Immunomedics’ drug | Fierce Biotech
Feb 10, 2017 - Seattle Genetics is to pay $250 million upfront for the rights to Immunomedics’ solid tu
seattle geneticspenspactbagdrug
https://www.pharmamanufacturing.com/industry-news/news/11311548/seattle-genetics-kills-2b-deal-with-immunomedics
Seattle Genetics Kills $2B Deal with Immunomedics | Pharma Manufacturing
What started out as a $250M licensing deal of a solid-tumor drug -- with potential milestone payments up to $2B -- ended after Immunomedics removed its top...
seattle geneticsdeal withkillsimmunomedicspharma
https://www.drugdeliverybusiness.com/seattle-genetics-wins-fda-breakthrough-therapy-designation-hodgkin-lymphoma-treatment/
Seattle Genetics wins FDA Breakthrough Therapy Designation for Hodgkin lymphoma treatment - Drug...
Oct 2, 2017 - Seattle Genetics wins FDA Breakthrough Therapy Designation for Hodgkin lymphoma treatment - Drug Delivery Business
seattle geneticsbreakthrough therapyhodgkin lymphomawinsfda